BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013;62:1523-8. [PMID: 23903238 DOI: 10.1136/gutjnl-2013-305300] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol 2016;68:2403-11. [PMID: 27159030 DOI: 10.1002/art.39738] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
3 Mesonero F, López-Sanromán A, Madariaga A, Soria A. [Ipilimumab-induced colitis: A new challenge for gastroenterologists]. Gastroenterol Hepatol 2016;39:233-8. [PMID: 26298799 DOI: 10.1016/j.gastrohep.2015.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflamm Bowel Dis 2016;22:1362-9. [PMID: 26919458 DOI: 10.1097/MIB.0000000000000741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
5 Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S; New York Crohn's and Colitis Organization. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016;14:58-64. [PMID: 26247164 DOI: 10.1016/j.cgh.2015.07.037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
6 Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Mosli MH, Feagan BG. Combination therapy for the treatment of Crohn's disease. Expert Opin Biol Ther 2015;15:1429-42. [PMID: 26211474 DOI: 10.1517/14712598.2015.1065249] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016;151:97-109.e4. [PMID: 27039969 DOI: 10.1053/j.gastro.2016.03.037] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
9 Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkandari W, Dehrab A, Muhanna Ghanem AA, Hasan E, Hayat S, Saleh K, Tarakmeh H, Ali Y. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int 2019;39:1483-97. [PMID: 31309293 DOI: 10.1007/s00296-019-04372-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kalman RS, Hartshorn K, Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015;21:428-35. [PMID: 25251059 DOI: 10.1097/MIB.0000000000000211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Katsanos KH, Roda G, Brygo A, Delaporte E, Colombel JF. Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2015;9:1043-1052. [PMID: 26163301 DOI: 10.1093/ecco-jcc/jjv122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
12 Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, Chang S, Axelrad JE. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022:izac035. [PMID: 35262671 DOI: 10.1093/ibd/izac035] [Reference Citation Analysis]
13 Malter L, Jain A, Cohen BL, Gaidos JKJ, Axisa L, Butterfield L, Rescola BJ, Sarode S, Ehrlich O, Cheifetz AS. Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. Inflamm Bowel Dis 2020;26:1445-50. [PMID: 32100018 DOI: 10.1093/ibd/izaa032] [Reference Citation Analysis]
14 Albishi AM, Chakik R, Bazeed M. Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy. Case Rep Gastrointest Med 2021;2021:5593067. [PMID: 33968453 DOI: 10.1155/2021/5593067] [Reference Citation Analysis]
15 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res 2018;16:194-208. [PMID: 29743832 DOI: 10.5217/ir.2018.16.2.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
17 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, Berinstein JA, Allin KH, Jess T. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol 2020;5:276-84. [PMID: 31836320 DOI: 10.1016/S2468-1253(19)30362-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
19 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
20 Taborelli M, Sozzi M, Del Zotto S, Toffolutti F, Montico M, Zanier L, Serraino D. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. PLoS One 2020;15:e0235142. [PMID: 32574216 DOI: 10.1371/journal.pone.0235142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Farshidpour M, Charabaty A, Mattar MC. Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol 2019;32:247-56. [PMID: 31040621 DOI: 10.20524/aog.2019.0351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Duquenne L, Gul H, Emery P. Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. Expert Opin Drug Saf 2019;18:11-9. [PMID: 30444672 DOI: 10.1080/14740338.2018.1549541] [Reference Citation Analysis]
23 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9:945-965. [PMID: 26294789 DOI: 10.1093/ecco-jcc/jjv141] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 27.0] [Reference Citation Analysis]
25 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
26 Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int 2019;39:610-20. [DOI: 10.1111/liv.14051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
27 Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis., PALGA Group., IBD/RCC Group. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget 2015;6:38336-47. [PMID: 26447542 DOI: 10.18632/oncotarget.5186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Kim J, Feagins LA. Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer. Dig Dis Sci 2020;65:22-30. [PMID: 31713121 DOI: 10.1007/s10620-019-05934-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Zhou J, Chang L, Guan Y, Yang L, Xia X, Cui L, Yi X, Lin G. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer. PLoS One 2016;11:e0159708. [PMID: 27459628 DOI: 10.1371/journal.pone.0159708] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
30 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
31 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
32 Ha CY. Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. Clin Geriatr Med 2014;30:67-78. [PMID: 24267603 DOI: 10.1016/j.cger.2013.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
33 Ha CY, Katz S. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2014;11:128-138. [PMID: 24345890 DOI: 10.1038/nrgastro.2013.241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]